The cost utility of pitolisant as narcolepsy treatment
Authors:
- 14 December 2019
- journal article
- research article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 141 (4) , 301-310
Abstract
Objectives The cost‐effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy. Studies suggest that pitolisant is both as effective as previously introduced drugs and is associated with fewer adverse effects. The objective in this study was to estimate the cost‐effectiveness of pitolisant as monotherapy, and pitolisant as an adjunctive treatment to modafinil, compared to standard treatment. Materials & Methods Calculations were performed using a Markov model with a 50‐year time horizon. Healthcare utilisation and quality‐adjusted life years (QALYs) for each treatment alternative were calculated assuming no treatment effect on survival. Probabilistic sensitivity analyses were performed for treatment effectiveness and healthcare cost parameters. Results The cost per additional quality‐adjusted life year was estimated at SEK 356 337 (10 SEK ≈1 Euro) for pitolisant monotherapy, and at SEK 491 128 for pitolisant as an adjunctive treatment, as compared to standard treatment. The cost‐effectiveness measure was demonstrated to be particularly sensitive to the assumptions made concerning indirect effects on total healthcare utilization and the pitolisant treatment cost. Conclusions The incremental cost‐effectiveness ratios were below the unofficial willingness‐to‐pay threshold at SEK 500 000. The estimated costs per additional QALY obtained here are likely to overestimate the true cost‐effectiveness ratio since significant potential indirect effects – pertaining both to labour‐market and household‐related productivity – of treatment are not taken into account.Keywords
This publication has 30 references indexed in Scilit:
- Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart reviewSleep Medicine, 2014
- Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialThe Lancet Neurology, 2013
- Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general populationSleep Medicine, 2013
- Comorbidity and Mortality of Narcolepsy: A Controlled Retro- and Prospective National StudySLEEP, 2013
- Health, social, and economic consequences of narcolepsy: A controlled national study evaluating the societal effect on patients and their partnersSleep Medicine, 2012
- Pitolisant, an Inverse Agonist of the Histamine H3 ReceptorClinical Neuropharmacology, 2012
- The histamine H3 receptor: from discovery to clinical trials with pitolisantBritish Journal of Pharmacology, 2011
- A 5-year prospective cohort study on health-related quality of life in patients with narcolepsySleep Medicine, 2011
- Narcolepsy with cataplexyThe Lancet, 2007
- Hypocretins (orexins) and sleep–wake disordersThe Lancet Neurology, 2005